Reuters logo
BRIEF-Circassia Pharma says Duaklir improves lung function in COPD patients
September 7, 2017 / 6:16 AM / 3 months ago

BRIEF-Circassia Pharma says Duaklir improves lung function in COPD patients

Sept 7 (Reuters) - Circassia Pharmaceuticals Plc

* Announces duaklir® successfully met primary endpoints in amplify phase iii study in chronic obstructive pulmonary disease

* Nda submission planned h1 2018 by partner astrazeneca

* Circassia has exclusive commercialisation rights to duaklir® in united states Source text for Eikon: Further company coverage: (Reporting By London Bureau)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below